Antonio P.
- Country
- Italy
- Department
- Oncologia Toracica
Research Overview
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Patients With Previously Treated TROP2-Positive Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
- Evaluation of Adagrasib Dosing Regimens in Previously Treated KRAS G12C-Mutant Non-Small Cell Lung Cancer Patients
Data & Insights
Has run more than one trial at 292 of 533 partner sites.
Specializations
Non-Small Cell Lung Cancer Expertise
Specializes in treating advanced forms of non-small cell lung cancer (NSCLC), with particular focus on cases involving genetic mutations and targeted therapies.
- EGFR Mutation Treatment
- HER2 Mutation Therapy
- Advanced Metastatic Disease
Investigates novel therapeutic approaches for patients with specific genetic alterations in NSCLC.
Targeted Therapy Applications
Focuses on developing and implementing targeted therapeutic strategies for lung cancer treatment, particularly involving specific molecular pathways.
- EGFR TKI Therapies
- Combination Treatment Approaches
- Resistance Management Strategies
Evaluates innovative drug combinations to overcome treatment resistance in lung cancer.
Precision Medicine Development
Advances personalized treatment approaches for lung cancer patients through molecular profiling and biomarker-driven therapies.
- Biomarker Analysis
- Treatment Response Assessment
- Novel Drug Development
Explores emerging therapeutic options for specific genetic subtypes of lung cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.